All right, everybody.

Welcome back to plenary session.

This is video edition.

This is the Zoom edition.

I put together a brilliant panel of experts to talk about the balance, the pros and cons of the academy versus the industry.

I have from left across my screen, at least, I'll do it that way.

I have Sanam Logavi, and she is a hematopathologist at M.D. Anderson Cancer

Center. She is an academic pathologist and a proud member of pathology Twitter. Sanam, thanks so much for

joining us. Thank you so much for having me. I'm really delighted to be here. We'll let people,

we're going to go through in a second, and you'll all tell us about your

careers and lives.

We have Papaheim, Aaron Goodman.

He looks like he's been touched by the son.

He might have been.

He's in San Diego, California.

Aaron Goodman, Papaheam, he is a practicing he malignancy expert, transplanter, and

a master of all trades.

That's what I call him. And we have, he should need no

introduction on this show, Dr. David Steensma. David Steensma has been a previous guest of this podcast.

Long time ago in person in Portland, Oregon. He is, of course, a longtime faculty member at the

Dana-Farber Cancer Center before that the Mayo Clinic. Now currently, he's switched. He's playing for Novartis now as part of the hematology division there.

And he's going to be able to talk about both sides of this question. So I thought, you know,

...